Speaker Lecture Titles

Speaker Lecture Titles

Partial list of confirmed speakers.

Name

Country

Lecture Title

Claudio A. Cuello Canada NEW PERSPECTIVES OF NGF METABOLISM AND THE CHOLINERGIC SYSTEM IN PRECLINICAL ALZHEIMER’S
Liana Apostolova USA TBA
Johannes Attems UK AGE ASSOCIATED TDP-43 PATHOLOGY
Tom Beach USA BIOPSIES FOR DIAGNOSTIC AND PROGRESSION BIOMARKERS IN NEURODEGENERATIVE DISEASE
Mathew Blurton Jones USA EXAMINING THE THERAPEUTIC POTENTIAL OF CRISPR-MODIFIED IPS-MICROGLIA
Mercè Boada Spain TBA
Guojun Bu USA CENTRAL AND PERIPHERAL APOE IN ALZHEIMER’S DISEASE
Samantha Budd-Haeberlein USA DEVELOPMENT OF THERAPEUTICS IN ALZHEIMER’S DISEASE
Luc Buee France TAU IMMUNOTHERAPY: INTRACELLULAR OU EXTRACELLULAR TARGET?
Frédéric Checler France BETA-SECRETASE-DERIVED C-TERMINAL FRAGMENTS OF BETA-‎APP AS EARLY TRIGGERS OF CELLULAR DYSFUNCTIONS AND ANATOMICAL STIGMATA IN ALZHEIMER’S DISEASE
Gaël Chételat France IMPACT OF PSYCHOAFFECTIVE FACTORS ON ALZHEIMER’S DISEASE RISK AND MEDITATION AS AN PROMISING PREVENTIVE APPROACH
Ornit Chiba-Falek USA MULTI-OMICS NAVIGATION OF ALZHEIMER’S AND PARKINSON’S GENETIC LANDSCAPES FROM SINGLE-CELL LENSES
Don Cleveland USA TBA
Jeffrey Cummings USA THE ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE:  THE CHANGING THERAPEUTIC LANDSCAPE
Bart De Strooper Belgium THE EARLY CELLULAR RESPONSES IN THE ALZHEIMER DISEASE BRAIN.
Marc Diamond USA MECHANISMS OF TAU PRION AMPLIFICATION
Karen Duff UK PATHOGENIC MECHANISMS IN THE TAUOPATHIES
David Eisenberg USA STRUCTURE-BASED DISCOVERY OF SMALL MOLECULES THAT DISAGGREGATE TAU FIBRILS FROM ALZHEIMER’S DISEASE
Adam Fleisher USA EVOLUTION TOWARDS PRACTICAL BIOMARKERS FOR RESEARCH AND DIAGNOSIS IN ALZHEIMER’S DISEASE
Nick Fox United Kingdom ULTRAFAST MRI AND BIOMARKERS TO IMPROVE DIAGNOSIS RATES IN DEMENTIA
Dan Frenkel Israel THE LINK BETWEEN TAU TO BETA-AMYLOID: THE ASTROCYTES PERSPECTIVE
Giovanni Frisoni SWITZERLAND THE MEMORY CLINIC OF THE FUTURE: BRAIN HEALTH SERVICES FOR SECONDARY PREVENTION OF DEMENTIA AND COGNITIVE IMPAIRMENT
James Galvin USA BUILDING A BETTER BRAIN – USING PRECISION MEDICINE APPROACHES FOR DEMENTIA PREVENTION RESEARCH
Angela Genge Canada THE EVOLUTION OF BIOMARKERS AND OUTCOME MEASURES IN ALS DRUG DEVELOPMENT
Klaus Gerwert Germany PROTEIN MISFOLDING AS BIOMARKER FOR ALZHEIMER´S DISEASE, PARKINSON´S DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS
Alison Goate USA ALZHEIMER’S DISEASE GENETICS IMPLICATES EFFEROCYTOSIS AND A DISEASE RISK HUB
Gabriel Gold Switzerland TBA
Todd Golde USA THE AMYLOID SCAFFOLD HYPOTHESIS
Maria Grazia Spillantini UK ASSOCIATION OF TMEM106B WITH HUMAN AGING
John Growdon USA TBA
Christian Haass Germany MICROGLIAL FUNCTION AND DYSFUNCTION IN AD
Harald Hampel USA DESIGNING THE NEXT GENERATION CLINICAL CARE AND DIAGNOSTIC PATHWAY FOR ALZHEIMER’S DISEASE
Oskar Hansson Sweden FLUID AND IMAGING BIOMARKERS FOR ALZHEIMER’S AND PARKINSON’S DISEASES
Susanne Hendrix USA TBA
Michael Heneka Germany INNATE IMMUNE METABOLISM DETERMINES MICROGLIAL Aß CLEARANCE CAPACITY
Joachim Herz USA THE EARLY ENDOSOME: A THERAPEUTIC HUB FOR THE PREVENTION OF ALZHEIMER’S DISEASE
Makato Higuchi Japan IN-VIVO IMAGING OF PROTEIN AGGREGATES IN DIVERSE NEURODEGENERATIVE DISORDERS: RELATION TO STRUCTURES OF PATHOLOGICAL FILAMENTS
Henne Holstege The Netherlands ESCAPING COGNITIVE DECLINE UNTIL EXTREME AGES: AN OMICS-STUDY OF COGNITIVELY HEALTHY CENTENARIANS
David Holtzman USA MICROGLIA-MEDIATED T CELL INFILTRATION DRIVES NEURODEGENERATION IN TAUOPATHY
Bradley Hyman USA UNDERSTANDING HETEROGENEITY IN ALZHEIMER DISEASE
Costantino Iadecola USA BORDER ASSOCIATED MACROPHAGES TAKE CENTER STAGE IN THE NEUROVASCULAR DYSFUNCTION OF APOE4
Ole Isaacson USA LIPID LOAD, EXCHANGE AND STORAGE INVOLVED IN THE DISEASE PROCESSES OF LEWY BODY DEMENTIA
Takeshi Iwatsubo Japan PET AND BIOMARKER CHARACTERIZATION OF PRECLINICAL AD IN THE JAPANESE TRIAL READY COHORT
Clifford Jack USA IN DEFENSE OF A BIOLOGICAL DEFINITION OF ALZHEIMER’S DISEASE
William Jagust USA ASSOCIATIONS WITH TAU AND COGNITION IN PRECLINICAL ALZHEIMER’S DISEASE
Beomseok Jeon Korea A MULTICENTER, CASE-CONTROL STUDY OF Α-SYNUCLEIN ACCUMULATION IN THE GASTROINTESTINAL TRACT OF PARKINSON’S DISEASE
Frank Laferla USA MODELING LATE-ONSET ALZHEIMER’S DISEASE IN MICE
Susan Landau USA TAU HETEROGENEITY IN ALZHEIMER’S DISEASE
Virginia Lee USA IN VITRO AND IN VIVO AMPLIFICATION OF PATHOLOGICAL AD-TAU AND LBD-A-SYNUCLEIN
Seung-Jae Lee Korea NEUROINFLAMMATION DRIVES COMPOUND PROTEINOPATHIES
Cynthia Lemere USA C3 LOWERING IN ADULT MICE PROTECTS AGAINST AGE-RELATED NEURODEGENERATION
Gregg Lemke USA THE DENSE-CORE PLAQUES OF ALZHEIMER’S DISEASE ARE GRANULOMAS
Stuart Lipton USA INHIBITION OF AUTOPHAGIC FLUX BY ABERRANT PROTEIN S-NITROSYLATION PROMOTES NEURONAL SECRETION AND CELL-TO-CELL TRANSMISSION OF AGGREGATED PROTEINS IN PARKINSON’S DISEASE/LEWY BODY DEMENTIA AND ALZHEIMER’S DISEASE
Eva Mandelkow Germany TREATMENTS AND REVERSAL OF TAU PATHOLOGY IN TRANSGENIC MICE
Eckhard Mandelkow Germany CELLULAR AND STRUCTURAL ASPECTS OF TAU PROTEIN AND TAU INTERACTIONS
Ken Marek USA DEVELOPING  PD PRODROMAL BIOMARKER SIGNATURE TO SUPPORT PRODROMAL THERAPEUTIC TRIALS
Eliezer Masliah USA THE INTERPLAY BETWEEN AGING, THE IMMUNE SYSTEM AND ALPHA-SYNUCLEIN IN THE PATHOGENESIS OF DLB/PD
Pamela McLean USA TBA
Daniel Michaelson Israel COUNTERACTING THE PATHOLOGICAL EFFECTS OF APOE4 BY ACTIVATION OF THE LIPIDATING PROTEIN ABCA1
Mark Mintun USA POTENTIAL ROLE OF PRECISION MEDICINE APPROACHES IN USING AMYLOID TARGETING THERAPIES
Asuka Morizane Japan MONITORING GRAFT SURVIVAL AND IMMUNE RESPONSE IN CELL REPLACEMENT THERAPY FOR PARKINSON’S DISEASE
John Morris USA ALZHEIMER BIOMARKER CORRELATIONS WITH MEASURES OF SOCIAL DETERMINANTS OF HEALTH
Ulrike Müller Germany HARNESSING THE PHYSIOLOGICAL FUNCTIONS OF APP FOR AD TREATMENT
Manuela Neumann Germany DISSECTING THE ROLE OF OLIGODENDROCYTES IN TDP-43 PROTEINOPATHIES
Henrietta Nielsen Sweden PERIPHERAL APOE-RELATED SIGNATURES
Tania Nikolcheva Switzerland LESSONS LEARNED FROM CLINICAL TRIALS IN ALZHEIMER’S AND PARKINSON’S DISEASES
Agneta Nordberg Sweden THE CLINICAL VALUE OF PLASMA BIOMARKERS IN A TERITARY MEMORY CLINIC – A COMPARISON WITH IMAGING AND CSF BIOMARKERS
Miranda Orr USA CELLULAR SENESCENCE AS A PATHOGENIC CONTRIBUTOR AND THERAPEUTIC TARGET IN ALZHEIMER’S DISEASE
Tiago Outerio Germany GLYCATION AS A TARGET FOR INTERVENTION IN SYNUCLEINOPATHIES
Ronald Petersen USA FLUID BIOMARKERS IN MILD COGNITIVE IMPAIRMENT
Werner Poewe Austria EVOLVING CONCEPTS IN THE DIAGNOSIS OF PD
Marco Prado Canada IMPROVING RESEARCH TRANSLATION IN DEMENTIA: HUMANIZED MOUSE MODELS, COGNITION AND IMAGING
Gill Rabinovici USA ALZ-NET: A U.S.-WIDE REGISTRY TO TRACK LONGITUDINAL OUTCOMES IN PATIENTS TREATED WITH NOVEL AD THERAPIES IN REAL WORLD CLINICAL PRACTICE
Laura Ranum USA TBA
Stephen Salloway USA NEW AND EMERGING TREATMENTS FOR ALZHEIMER’S DISEASE
Philip Scheltens The Netherlands ALZHEIMER: THE SEARCH FOR BETTER TARGETS AND MEANINGFUL OUTCOMES
Sjors Scheres UK CRYO-EM STRUCTURES OF AMYLOIDS FROM HUMAN BRAIN
Michael Schlossmacher Canada EXAMINATION OF THE OLFACTORY EPITHELIUM AND CRANIAL NERVE-1 IN AUTOPSY CASES OF COVID19 AND NEURODEGENERATION
Taylor Schmitz Canada TRANSLATIONAL POTENTIAL FOR MULTIMODAL IMAGING OF CHOLINERGIC PHENOTYPES IN MICE
Julie Schneider USA TBA
Menachem Segal Israel TBA
Dennis Selkoe USA THE FIRST DISEASE-MODIFYING TREATMENTS FOR AD: A GLASS HALF FULL
Jie Shen USA NOVEL THERAPIES OF FAMILIAL ALZHEIMER’S DISEASE
Tamara Shiner Israel IMAGING MARKERS IN GBA RELATED DEMENTIA WITH LEWY BODIES
Sam Sisodia USA THE GUT MICROBIOME MODULATES AD-LIKE PHENOTYPES IN MOUSE MODELS
Beka Solomon Israel ALZHEIMER’S DISEASE AND IMMUNOTHERAPY
Mona Soreq Israel TRANSFER RNA FRAGMENTS CARRYING A COMMON SEQUENCE MOTIF CAUSE SUPPRESSIBLE PARKINSON’S DISEASE NEURONAL DEATH VIA TRANSLATIONAL ARREST
Reisa Sperling USA AMYLOID, TAU, AND COGNITIVE DECLINE DURING THE PRECLINICAL STAGES OF ALZHEIMER’S DISEASE
Peter St. George-Hyslop Canada ROLE OF MICROGLIAL RISK AND RESILIENCE GENES IN REGULATING MICROGLIAL SIGNALLING AND FUNCTION
Beth Stevens USA NEUROIMMUNE MECHANISMS OF ALZHEIMER’S DISEASE : MAPPING GENETIC VARIANT TO FUNCTION IN BRAIN ASSOCIATED MACROPHAGES
Fabrizio Stocchi Italy NEW INSIGHT IN THE TREATMENT OF PARKINSONS DISEASE
Thomas Sudhof


Nobel Prize Winner
USA CONNECTING LIPID METABOLISM TO SYNAPTIC DYSFUNCTION IN ALZHEIMER’S DISEASE
Malu Tansey USA TARGETING INNATE IMMUNE DYSFUNCTION AND CHRONIC INFLAMMATION IN THE GUT-BRAIN AXIS TO LOWER RISK AND PROGRESSION OF NEURODEGENERATION
Rudy Tanzi USA ALZHEIMER’S DISEASE IS A GENETICALLY COMPLEX AND HETERGENEOUS INNATE IMMUNE DISORDER
Maria Teresa Ferretti Switzerland LEVERAGING SEX DIFFERENCES FOR IMPROVED PREVENTION, DIAGNOSTICS AND TREATMENT – THE WORK OF THE WOMEN’S BRAIN PROJECT
Li-Huei Tsai USA LIPID DYSREGULATION IS A COMMON PATHOGENIC MECHANISM OF MAJOR ALZHEIMER’S DISEASE RISK GENES
Christine Van Broeckhoven Belgium CONTRIBUTION OF RARE GENETIC VARIANTS TO NEURODEGENERATIVE BRAIN DISEASES
Robert Vassar USA ANNEXIN A6 OVEREXPRESSION REDUCES DYSTROPHIC NEURITE FORMATION AND PATHOLOGIC TAU PHOSPHORYLATION IN 5XFAD MICE
Yaning Wang USA FACTS AND MISCONCEPTIONS ABOUT ADUCANUMAB APPROVAL
Carina Wattmo SWEDEN SEX DIFFERENCES IN DISEASE PROGRESSION IN ALZHEIMER PATIENTS WITH DIFFERENT CONCOMITANT MEDICATIONS
Howard L. Weiner USA IMMUNOTHERAPY OF ALZHEIMER’S DISEASE BY MODULATION OF INNATE IMMUNITY
Michael Weiner USA USING DIGITAL AND FLUID BIOMARKERS FOR SCREENING AND SELECTION INTO THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE
Cheryl Wellington Canada LIPOPROTEINS IN ALZHEIMER’S DISEASE
Donna Wilcock USA DISEASE INSIGHTS FROM NOVEL PLASMA BIOMARKERS OF MULTI-ETIOLOGY DEMENTIA
Bengt Winblad SWEDEN DEVELOPMENT OF TREATMENT WITH SMALL MOLECULES FOR ALZHEIMER DISEASE
Huaxi Xu USA A NOVEL IMMUNOTHERAPY FOR TAUOPATHY
Henrik Zetterberg Sweden THE USE OF BLOOD BIOMARKERS IN EARLY DIAGNOSIS AND CLINICAL TRIAL OUTCOMES
Jiawei Zhou China NON-CANONICAL ROLE OF INTESTINAL DOPAMINE RECEPTOR SIGNALLING IN NEURODEGENERATION
Berislav Zlokovic USA BLOOD-BRAIN BARRIER ROLE IN NEURODEGENERATION, COGNITIVE DECLINE AND ALZHEIMER’S DISEASE